{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"10.9","value":"9.2"},{"groupId":"OG001","lowerLimit":"6.9","upperLimit":"8.3","value":"7.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of randomisation until documented progression (according to the mRECIST v1.1) or death, if progression is not documented. Censoring (for participants without a PFS/death event) will occur at the date of last tumour assessment. Patients without a post-baseline tumour assessment will be censored at the date of randomization (plus 1 day).","dispersionType":"95% Confidence Interval","groups":[{"description":"Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG000","title":"Atezolizumab Plus Bevacizumab Plus Chemotherapy"},{"description":"Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG001","title":"Bevacizumab Plus Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Efficacy population (Intention-To-Treat cohort of all randomised patients)","reportingStatus":"POSTED","timeFrame":"From randomization until documented progression (PD) according to mRECIST v1.1 or death from any cause (whichever occurred first), up to 52 months.","title":"Progression-free Survival (PFS) According to the mRECIST v1.1","type":"SECONDARY","unitOfMeasure":"months"}